STOCK TITAN

ICON PLC SEC Filings

ICLR NASDAQ

Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

ICON PLC’s SEC reports can feel as dense as a clinical trial protocol—buried inside the 10-K are pages on backlog conversion rates, post-acquisition synergies, and laboratory service margins. Hunting for a single note on patient-recruitment risk or integration costs consumes precious time. Stock Titan’s platform surfaces the answers instantly, giving you an AI-powered shortcut to ICON PLC SEC filings explained simply.

Whether you need an ICON PLC annual report 10-K simplified to spot goodwill impairment triggers, or an ICON PLC quarterly earnings report 10-Q filing to track revenue by Phase III study, every document arrives in real time from EDGAR. Our AI breaks down:

  • Form 4 insider transactions—get ICON PLC Form 4 insider transactions real-time alerts and visualize buying or selling before key data readouts.
  • 8-K material events—see “ICON PLC 8-K material events explained”, from large contract wins to unexpected trial discontinuations.
  • Proxy statements—quickly compare ICON PLC proxy statement executive compensation against peer CROs.

Practical use cases follow naturally: monitor ICON PLC executive stock transactions Form 4 ahead of earnings, compare backlog growth quarter-over-quarter, or gauge acquisition integration costs without wading through footnotes. From "understanding ICON PLC SEC documents with AI" to "ICON PLC earnings report filing analysis", Stock Titan equips life-sciences investors with clear summaries, expert context, and searchable, always-current filings—so you can focus on decisions, not document hunts.

Rhea-AI Summary

ICON (Nasdaq:ICLR) filed a routine Form 6-K that simply furnishes Exhibit 99.1 titled “ICON plc Schedules Second Quarter 2025 Earnings Conference Call.” The notice contains no financial statements, guidance, or operational updates. It also confirms the company continues to file annual reports on Form 20-F. The document was signed by Chief Financial Officer Nigel Clerkin on 23 June 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
current report
-
Rhea-AI Summary

ICON plc (Nasdaq: ICLR) has submitted a routine Form 6-K dated 18 June 2025 to the U.S. Securities and Exchange Commission. The filing confirms that the company continues to report under Form 20-F requirements for foreign private issuers and is signed by Chief Financial Officer Nigel Clerkin.

The sole attachment, listed as Exhibit 99.1, contains the company’s Unaudited Interim IFRS Single Company Financial Statements. No numerical results, earnings data, or transaction details are provided in the cover document itself. As such, the submission appears to be an administrative update intended to place the interim financial statements on the public record.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of ICON PLC (ICLR)?

The current stock price of ICON PLC (ICLR) is $144.56 as of June 28, 2025.

What is the market cap of ICON PLC (ICLR)?

The market cap of ICON PLC (ICLR) is approximately 11.7B.

What is the primary business of ICON PLC?

ICON PLC is a global contract research organization that provides outsourced clinical development and trial management services to the pharmaceutical, biotechnology, and medical device industries.

Which industries are served by ICON PLC?

The company serves the pharmaceutical, biotechnology, and medical device sectors, offering a broad range of clinical research, development, and pharmacovigilance services.

What range of services does ICON offer?

ICON offers clinical trial management, end-to-end pharmacovigilance, ancillary laboratory and imaging support, and advanced data analytics to streamline the drug development process.

How does ICON ensure quality and regulatory compliance?

Through rigorous oversight, standardized trial protocols, and adherence to international regulatory standards, ICON maintains robust quality control and patient safety throughout its clinical trials.

What differentiates ICON's business model?

ICON's ability to provide both stand-alone services and integrated full service solutions with operational flexibility enables it to efficiently manage clinical trials on local and global scales.

How does technology play a role in ICON's operations?

ICON integrates advanced digital tools and collaborative partnerships to enhance participant management, streamline administrative processes, and improve efficiency in clinical trial operations.
ICON PLC

NASDAQ:ICLR

ICLR Rankings

ICLR Stock Data

11.71B
78.96M
0.61%
98.56%
2.09%
Diagnostics & Research
Healthcare
Link
Ireland
Dublin